- Home
- GMAB vs TRU Comparison
GMAB vs TRU Comparison
Compare GMAB & TRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TRU
- Stock Information
- Founded
- GMAB 1999
- TRU 1968
- Country
- GMAB Denmark
- TRU United States
- Employees
- GMAB N/A
- TRU N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TRU Finance: Consumer Services
- Sector
- GMAB Health Care
- TRU Finance
- Exchange
- GMAB Nasdaq
- TRU Nasdaq
- Market Cap
- GMAB 17.4B
- TRU 16.6B
- IPO Year
- GMAB N/A
- TRU 2015
- Fundamental
- Price
- GMAB $28.66
- TRU $80.10
- Analyst Decision
- GMAB Strong Buy
- TRU Buy
- Analyst Count
- GMAB 7
- TRU 12
- Target Price
- GMAB $41.17
- TRU $104.45
- AVG Volume (30 Days)
- GMAB 2.6M
- TRU 3.0M
- Earning Date
- GMAB 11-06-2025
- TRU 10-23-2025
- Dividend Yield
- GMAB N/A
- TRU 0.58%
- EPS Growth
- GMAB 77.72
- TRU 87.22
- EPS
- GMAB 21.62
- TRU 2.14
- Revenue
- GMAB $3,646,881,232.00
- TRU $4,441,800,000.00
- Revenue This Year
- GMAB $24.92
- TRU $8.06
- Revenue Next Year
- GMAB $15.97
- TRU $8.36
- P/E Ratio
- GMAB $12.96
- TRU $36.93
- Revenue Growth
- GMAB 32.97
- TRU 8.30
- 52 Week Low
- GMAB $17.24
- TRU $66.38
- 52 Week High
- GMAB $33.65
- TRU $108.12
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- TRU 44.54
- Support Level
- GMAB $28.08
- TRU $79.02
- Resistance Level
- GMAB $29.35
- TRU $80.80
- Average True Range (ATR)
- GMAB 0.65
- TRU 2.26
- MACD
- GMAB -0.27
- TRU -0.00
- Stochastic Oscillator
- GMAB 25.93
- TRU 17.20
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.